GlassScriptPhysician profile
Asad Majid
NPI 1982778254
$5,458.41
in general payments reported to CMS, 2019-2025
29 companies · $1,550 in 2025
The $1,550 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $350 · 2021: $647 · 2022: $640 · 2023: $1,031 · 2024: $1,240 · 2025: $1,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,668.50 |
| Education | $152.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $952.33 | 2020-2025 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $401.00 | 2020-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $367.36 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $336.93 | 2020-2025 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $299.95 | 2020-2025 | Rayaldee |
| Vifor Pharma, INC. | $278.44 | 2020-2023 | Veltassa, Korsuva |
| Takeda Pharmaceuticals U.S.A., INC. | $228.19 | 2022-2024 | Gattex |
| Astrazeneca Pharmaceuticals LP | $211.31 | 2020-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $208.65 | 2023-2025 | |
| Akebia Therapeutics INC | $208.59 | 2020-2024 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $194.72 | 2021-2025 | |
| Lilly USA, LLC | $192.23 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $155.85 | 2020-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $152.84 | 2022-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $149.07 | 2024-2025 | Acthar, Terlivaz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $147.63 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.06 | 2024-2025 | Jardiance |
| Horizon Therapeutics Plc | $122.02 | 2021-2023 | Krystexxa |
| Novo Nordisk INC | $115.93 | 2024-2025 | Wegovy, Ozempic |
| Alexion Pharmaceuticals, INC. | $105.57 | 2021-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $99.54 | 2022-2023 | |
| Genzyme Corporation | $80.98 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $73.63 | 2022-2025 | Voyxact |
| Daiichi Sankyo INC. | $73.41 | 2021 | |
| Alnylam Pharmaceuticals INC. | $53.75 | 2024 | Onpattro |
| Chiesi USA, INC. | $41.23 | 2025 | Elfabrio |
| Amicus Therapeutics, INC. | $37.87 | 2021-2023 | Galafold |
| Apellis Pharmaceuticals, INC. | $23.21 | 2025 | |
| Ani Pharmaceuticals, INC. | $20.12 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Majid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.